Israel Multicenter D-Serine Study (IMSER) for the Treatment of Schizophrenia
NCT ID: NCT00138775
Last Updated: 2006-12-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
200 participants
INTERVENTIONAL
2004-10-31
2007-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The investigators are hypothesizing that D-serine will improve cognitive functioning and negative symptoms.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
D-serine
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age between 18 to 64.
* PANSS negative symptom score higher than 19.
* SAS total score lower than 12.
* CDSS suicidal risk lower than 2
Exclusion Criteria
* Meets DSM-IV criteria for mental retardation.
* Medical condition which confounds presentation or treatment (e.g. uncontrolled diabetes mellitus, history of kidney stones, acute drug toxicity, dementia, delirium, stroke, etc.)
* Meets DSM-IV criteria for alcohol or drug dependence in last 6 months.
* Meets DSM-IV criteria for alcohol or drug abuse in last one month.
* Treatment with clozapine.
* Current positive pregnancy test or not using acceptable method of birth control.
* Meets DSM-IV criteria for current anxiety or mood disorders
18 Years
64 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Stanley Medical Research Institute
OTHER
Sheba Medical Center
OTHER_GOV
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mark Weiser, MD
Role: PRINCIPAL_INVESTIGATOR
Sheba Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mazra Mental Health Center
Acre, , Israel
Ha-Emek Medical Center
Afula, , Israel
Abarbanel Mental Health Center
Bat Yam, , Israel
Beer-Yaacov Mental Health Center
Beer-Yaacov, , Israel
Shalvata Mental Health Center
Hod HaSharon, , Israel
Kfar Shaul Psychiatric Hospital
Jerusalem, , Israel
The Sarah Herzog Memorial Hospital
Jerusalem, , Israel
Nes-Ziona Mental Health Center
Ness Ziona, , Israel
Lev Hasharon Mental Health Center
Pardesiyya, , Israel
Geha Mental Health Center
Petah Tikva, , Israel
Sheba Medical Center
Ramat Gan, , Israel
Shaar Menashe Mental Health Center
Shaar Menashe, , Israel
Jaffa Mental Health Center
Tel Aviv, , Israel
Maccabi Mental Health Center
Tel Aviv, , Israel
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
David Liba, MD
Role: primary
Ilana Kremer, MD
Role: primary
Motti Mashiah, MD
Role: primary
Yehuda Abramovitch, MD
Role: primary
Yehiel Levkovitch, MD
Role: primary
Alexander Teitelbaum, MD
Role: primary
Uriel Heresco-Levy, MD
Role: primary
Daniela Amital, MD
Role: primary
Dimitri Rudinski, MD
Role: primary
Shai Konas, MD
Role: primary
Mark Weiser, MD
Role: primary
Shmuel Hirschmann, MD
Role: primary
Yosef Zimerman, MD
Role: primary
Yerechmiel Barber, MD
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Weiser M, Heresco-Levy U, Davidson M, Javitt DC, Werbeloff N, Gershon AA, Abramovich Y, Amital D, Doron A, Konas S, Levkovitz Y, Liba D, Teitelbaum A, Mashiach M, Zimmerman Y. A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia. J Clin Psychiatry. 2012 Jun;73(6):e728-34. doi: 10.4088/JCP.11m07031.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SHEBA-03-3093-MW-CTIL
Identifier Type: -
Identifier Source: org_study_id